HomeORINY • OTCMKTS
add
Orion Oyj Unsponsored Finland ADR
Previous close
$23.36
Year range
$17.50 - $28.55
Market cap
6.43B EUR
Avg Volume
34.00
Financials
Income Statement
Revenue
Net income
| (EUR) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 471.30M | 56.53% |
Operating expense | 117.40M | 28.73% |
Net income | 160.80M | 161.89% |
Net profit margin | 34.12 | 67.34% |
Earnings per share | 1.14 | 159.09% |
EBITDA | 215.00M | 129.70% |
Effective tax rate | 20.20% | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 190.10M | 144.03% |
Total assets | 1.61B | 17.17% |
Total liabilities | 683.30M | 28.51% |
Total equity | 924.40M | — |
Shares outstanding | 140.50M | — |
Price to book | 3.55 | — |
Return on assets | 32.95% | — |
Return on capital | 45.77% | — |
Cash Flow
Net change in cash
| (EUR) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | 160.80M | 161.89% |
Cash from operations | 67.20M | 103.64% |
Cash from investing | -22.10M | 2.64% |
Cash from financing | -7.60M | 10.59% |
Net change in cash | 37.60M | 1,039.39% |
Free cash flow | 67.88M | 1,674.51% |
About
Orion Corporation, founded in 1917 and headquartered at Espoo, Finland, is a globally operating Finnish company which develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients for global markets. All of the company's manufacturing sites and the majority of its R&D units are in Finland.
Orion's class A and B shares are listed on the Helsinki Stock Exchange. Wikipedia
CEO
Founded
1917
Website
Employees
3,867
